CRISPR Therapeutics in 2026: Casgevy's Commercial Reality, Base Editing, Prime Editing, and the In-Vivo Race
Vertex/CRISPR's Casgevy commercial reality post-approval, Editas, Intellia's in-vivo work, Beam Therapeutics base editing, Prime Medicine, Verve PCSK9, and what the post-Casgevy clinical landscape actually looks like.
The CRISPR therapeutics story in 2026 has matured beyond the breathless press-release era into something stranger and more interesting — a field with an FDA-approved product whose commercial uptake has been much slower than anyone modelled, in-vivo trials that finally crossed early proof-of-concept, and an editing-toolkit expansion from cutting to base editing to prime editing that is changing what gets clinical. The Casgevy approval in December 2023 was the field’s victory lap. The 2025-2026 reality is that the next products in the pipeline will not look much like Casgevy commercially or technically.
This is the engineer-friendly map of where the field actually sits.
Casgevy and the commercial reality#
Casgevy — exagamglogene autotemcel, the joint Vertex Pharmaceuticals and CRISPR Therapeutics product — was approved by the UK MHRA in November 2023 and the US FDA in December 2023 for sickle cell disease, followed by the beta-thalassemia indication in January 2024. The product is an autologous ex-vivo edited cell therapy: collect a patient’s hematopoietic stem cells, edit them with CRISPR-Cas9 to reactivate fetal hemoglobin (the BCL11A erythroid enhancer cut), expand and verify them, then reinfuse after myeloablative conditioning. The clinical results have been excellent — most treated patients are functionally cured.
The commercial story has been harder. The list price is just over 2 million USD per patient. Vertex’s authorized treatment centers in the US — fewer than 50 at launch, with slow expansion through 2024-2025 — are bottlenecked on apheresis and conditioning capacity. The myeloablative conditioning regimen carries real risks and requires weeks of hospitalization. Insurance approvals have been case-by-case rather than systematic. Through 2024 and into 2025 the number of actual patients treated annually was in the hundreds rather than thousands, against a US sickle-cell population in the hundreds of thousands.
The honest reading: Casgevy proved that CRISPR can be a regulated medicine. It did not prove that ex-vivo autologous cell therapy is a scalable commercial pattern. The next generation of CRISPR products will largely try to avoid the autologous workflow entirely.
The shift to in-vivo#
The biggest scientific shift in 2024-2026 has been in-vivo editing — delivering the CRISPR machinery directly into the patient’s body, usually with lipid nanoparticles, rather than editing cells in a clean room and reinfusing them. In-vivo skips the apheresis, conditioning, and cell-manufacturing entirely. It also opens many more diseases — anything where the target tissue is the liver, the eye, the inner ear, or various other delivery-tractable organs.
Intellia Therapeutics is the in-vivo leader. NTLA-2001 for transthyretin amyloidosis (ATTR) — delivered as an LNP to the liver, knocks out TTR — completed Phase 2 through 2024 and entered Phase 3 in late 2024. The 2024 interim data showed durable reductions in serum TTR levels approaching the magnitude of patisiran (the existing siRNA standard of care) but with a single dose rather than chronic infusion. NTLA-2002 for hereditary angioedema is on a similar arc.
Editas Medicine pivoted through 2024-2025 to focus on in-vivo programs after the EDIT-101 trial in Leber congenital amaurosis (LCA10) wound down. The pivot reflected the broader field’s recognition that ex-vivo cell therapy outside of hematopoietic disease is a hard commercial path.
The in-vivo cardiac and CNS targets are the hardest — delivery to heart muscle, brain, and skeletal muscle still does not have a reliable workhorse comparable to LNP-to-liver. Several startups including Tessera, Verve, and CRISPR’s own pipeline are working on this, with results still mostly preclinical.
Base editing — Beam, Verve, and the precision argument#
Cas9 makes double-strand breaks, which the cell repairs with error-prone non-homologous end joining. That works for knocking genes out but is a poor tool for precise edits. Base editors — invented by David Liu’s lab and commercialized primarily through Beam Therapeutics — fuse a deactivated Cas9 to a deaminase that chemically converts one DNA base to another without cutting either strand. Adenine base editors (ABEs) and cytidine base editors (CBEs) cover the most clinically important transitions.
Beam Therapeutics has BEAM-101 for sickle cell in clinical trials — an autologous ex-vivo base-edited cell product designed to outperform Casgevy on safety and durability. The 2024-2025 readouts have been encouraging on the engraftment and HbF reactivation metrics. BEAM-302 for alpha-1 antitrypsin deficiency is an in-vivo LNP-to-liver program in early clinical work.
Verve Therapeutics is the high-profile in-vivo base-editing story. VERVE-102 targets PCSK9 — knocking out the gene in liver cells lowers LDL cholesterol durably with a single dose. The original VERVE-101 program was paused in 2023 after a safety signal; VERVE-102, redesigned with a different LNP and base-editor combination, restarted in 2024 and the 2024-2025 readouts showed durable LDL reduction in treated patients. If the Phase 2 program holds, this becomes the first chronic-disease in-vivo base-editing therapy.
Prime editing — Prime Medicine and the precise edits#
Prime editing — also from the Liu lab, commercialized through Prime Medicine — uses a Cas9 nickase fused to a reverse transcriptase, with a guide that carries both the target sequence and the desired edit as an RNA template. This enables small insertions, deletions, and all twelve possible base substitutions without double-strand breaks. The precision advantage over base editing is real but the delivery and efficiency challenges are also real.
Prime Medicine has PM359 for chronic granulomatous disease (CGD) — an autologous ex-vivo program — in clinical trials, with the 2024-2025 results being the field’s first published prime-editing clinical data. The in-vivo prime-editing programs are several years behind base editing on the development timeline.
The strategic question for prime editing is whether the precision benefit justifies the engineering complexity for diseases where base editing already works. For diseases that need insertions or deletions or specific transversions, prime editing is the only CRISPR-toolkit option that does it without double-strand breaks.
The other delivery problem — beyond LNP and AAV#
In-vivo CRISPR is largely two delivery vehicles in 2026: lipid nanoparticles (for the liver) and adeno-associated virus (for the eye, the inner ear, and increasingly CNS). Both have hard limits. LNPs cannot reach most tissues outside the liver and spleen with current chemistry. AAV has packaging limits (the Cas9 gene alone fills most of the capsid) and pre-existing immunity issues.
The 2025-2026 delivery work that matters: targeted LNPs (Capstan Therapeutics’ in-situ CAR-T, Orna Therapeutics’ circular RNA, several venture-backed efforts on antibody-conjugated LNPs), engineered AAV capsids (Sangamo, Voyager Therapeutics’ TRACER), and entirely new delivery modalities (eGenesis on porcine xenotransplantation as a complementary approach, Tessera’s “writes to the genome” work using mobile genetic elements). None of these has the maturity of LNP-to-liver, but the next-generation in-vivo CRISPR products will need at least one to work outside the liver.
What this looks like for healthcare platforms#
For a healthcare CIO or platform team in 2026, the CRISPR question is no longer scientific curiosity — it is a real operational and reimbursement workflow. The Casgevy treatment journey is one of the most data-intensive in modern medicine: apheresis, cell processing, conditioning, infusion, multi-year follow-up. The teams that built hospital management systems for cell-therapy centers have a real backlog of pipeline work — patient screening, treatment-center logistics, outcomes reporting to regulators, and the registries that authorize future products. We have helped systems wire this up.
The in-vivo wave is likely to compress the workflow but expand the patient population. A single-dose LNP that lowers LDL durably is a very different clinical pattern from an autologous cell therapy — it looks more like a one-time vaccination than a transplant — and the platforms supporting it will look different too.
Related reading#
CRISPR is finally a regulated medicine and the next wave is in-vivo. If your healthcare organization is sizing the platform for cell-therapy or in-vivo programs, our data engineering team has wired up the registries and outcomes pipelines for clinical workflows. Tell us about the program.